Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company committed to enhancing drug delivery and efficacy through its proprietary PRINT® technology. The company focuses on the development, manufacturing, and commercialization of innovative therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s flagship product, YUTREPIA™, is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and PH-ILD. This product aims to improve exercise ability and quality of life for patients.
Liquidia is actively advancing its product pipeline, which includes L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer. Currently, L606 is under evaluation in an open-label study and aims to extend drug exposure while minimizing local irritation in the lungs.
In addition to these developments, Liquidia has a valuable collaboration with leading pharmaceutical companies, leveraging its PRINT® technology for broader therapeutic areas. This technology enables precise production of uniform drug particles, enhancing safety and efficacy, and can be applied to various therapeutic areas and routes of administration.
Recent achievements include the promotion of key leadership within the company as they prepare for the potential FDA approval and launch of YUTREPIA. The company has also successfully navigated regulatory and legal challenges, ensuring a clear path for YUTREPIA’s market entry.
Financially, Liquidia has demonstrated robust growth, reporting significant revenue from its partnership with Sandoz for the commercial sale of Treprostinil Injection. The company has also secured substantial funding through strategic agreements, bolstering its cash reserves for continued research and development efforts.
Liquidia remains dedicated to transforming patient care by addressing unmet needs with innovative drug delivery solutions and is poised to make significant strides in the biopharmaceutical industry.
Liquidia (NASDAQ: LQDA) announced that the U.S. District Court for New Jersey has found United Therapeutics' interference with the launch of generic Treprostinil Injection caused losses exceeding $137 million. This decision stems from a 2019 lawsuit filed by Liquidia PAH and Sandoz against United Therapeutics, alleging violations of antitrust laws and unfair competition. The court granted partial summary judgments in March 2022 and has now determined damages from the breach of contract by United Therapeutics.
The final damage award is yet to be determined and will be offset by costs avoided by Sandoz. Proceeds from the litigation will be split equally between Sandoz and Liquidia PAH, with Liquidia PAH's share further divided between Henderson SPV, and PBM RG Holdings, due to litigation finance agreements.
Liquidia (NASDAQ: LQDA) has announced significant financial developments, including:
1. A $67.5 million raise through an underwritten public offering and a concurrent private placement, offering shares at $8.90 per share.
2. An additional $32.5 million funding from HealthCare Royalty (HCRx) through an amendment to their Revenue Interest Financing Agreement (RIFA).
These actions will provide Liquidia with approximately $100 million in gross proceeds. The funds will support the ongoing commercial development of YUTREPIA™ for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), as well as other clinical trials and the development of L606.
Bronstein, Gewirtz & Grossman, is investigating potential claims against Liquidia Technologies, Inc. (NASDAQ:LQDA) on behalf of shareholders. The investigation follows Liquidia's announcement on August 19, 2024, that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder for treating PAH and PH-ILD in adults. However, final approval is delayed due to a competing product's regulatory exclusivity.
Following this news, Liquidia's stock price fell 30.62%, closing at $9.79 per share. Investors who purchased Liquidia securities are encouraged to assist the investigation. The law firm is representing investors on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary diseases, has announced its participation in two upcoming investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, from 11:00 to 11:35 a.m. ET, and at the 2024 Cantor Global Healthcare Conference in New York on September 19, from 1:30 to 1:50 p.m. ET.
Investors and interested parties can access the webcasts of these presentations through Liquidia's website. Recorded versions of the presentations will be available on the company's website for at least 30 days following each event, providing an opportunity for those unable to attend live to review the information presented.
Bronstein, Gewirtz & Grossman, is investigating potential claims against Liquidia Technologies, Inc. (NASDAQ: LQDA) on behalf of investors. The investigation follows Liquidia's announcement on August 19, 2024, that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder for treating PAH and PH-ILD in adults. However, final approval is delayed due to a competing product's regulatory exclusivity. This news caused Liquidia's stock to drop 30.62%, closing at $9.79 per share. Investors who purchased LQDA securities are encouraged to participate in the investigation. The law firm is operating on a contingency fee basis, seeking reimbursement only if successful.
Bronstein, Gewirtz & Grossman, is investigating potential claims against Liquidia Technologies, Inc. (NASDAQ:LQDA) on behalf of its shareholders. The investigation follows Liquidia's announcement on August 19, 2024, that the FDA granted tentative approval for YUTREPIA™, their inhalation powder for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, final approval is delayed due to a competing product's regulatory exclusivity. This news caused Liquidia's stock price to drop 30.62%, closing at $9.79 per share. Shareholders are encouraged to assist in the investigation and can contact the firm for more information.
Liquidia (NASDAQ: LQDA) has filed a lawsuit challenging the FDA's decision to grant 3-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI®. This exclusivity is delaying the final approval of Liquidia's YUTREPIA™ (treprostinil) inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) until after May 23, 2025.
Liquidia argues that the FDA's decision violates congressional intent, which allows NCI exclusivity only for true innovations supported by new clinical studies demonstrating safety and/or efficacy. The company believes this exclusivity should be vacated, allowing YUTREPIA to enter the market immediately. Separately, United Therapeutics has voluntarily dismissed its complaint against the FDA challenging the acceptance of Liquidia's amended NDA for YUTREPIA.
Liquidia (NASDAQ: LQDA) has received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval indicates that YUTREPIA meets all regulatory standards but must await the expiration of a competing product's exclusivity before final approval. The FDA confirmed that Liquidia's amendment to add PH-ILD to the YUTREPIA NDA was proper. Final approval may occur after May 23, 2025, following the expiration of Tyvaso DPI's 3-year regulatory exclusivity. The tentative approval is based on the Phase 3 INSPIRE trial results, which showed YUTREPIA to be safe and well-tolerated in both treprostinil-naïve patients and those transitioning from nebulized treprostinil.
Liquidia (NASDAQ: LQDA) announced the presentation of nine encore thematic posters at the PHA 2024 International PH Conference and Scientific Sessions in Indianapolis, Indiana. The posters, to be presented on August 16-17, 2024, focus on the company's investigational products: YUTREPIA™ (treprostinil inhalation powder) and L606 (liposomal treprostinil inhalation suspension sustained-release formulation). These products are being developed for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The posters cover various aspects of clinical trials, including safety, efficacy, pharmacokinetics, and quality of life assessments for both YUTREPIA™ and L606. Key studies presented include the INSPIRE study for YUTREPIA™ and a Phase 3 study for L606. The presentations also explore innovative approaches such as cardiac effort measurement and high-resolution computed tomography for drug deposition analysis.
Liquidia (NASDAQ: LQDA) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Cash and cash equivalents: $133.1 million as of June 30, 2024
- Revenue: $3.7 million, down from $4.8 million in Q2 2023
- Net loss: $27.9 million ($0.37 per share), compared to $23.5 million ($0.36 per share) in Q2 2023
The company progressed litigation, maintaining a clear legal path for FDA approval of YUTREPIA for PAH and PH-ILD treatment. Clinical studies for YUTREPIA and L606 advanced, with new data presented at medical conferences. Liquidia remains ready to launch YUTREPIA pending FDA approval.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
What is Liquidia Corporation's primary focus?
What is YUTREPIA?
What is PRINT® technology?
What products are in Liquidia’s pipeline?
How does Liquidia generate revenue?
What recent leadership changes have occurred at Liquidia?
What is the current status of YUTREPIA’s FDA approval?
What are the financial highlights for Liquidia?
What legal challenges has Liquidia faced?
How can I learn more about Liquidia Corporation?
